Cryopyrin-Associated Periodic Syndromes: Difficult to Recognize, Diagnose, Treat

Philip J. Hashkes, MD, MSc, works in the Pediatric Rheumatology Unit of Shaare Zedek Medical Center, in Jerusalem, Israel.
Ronald M. Laxer, MDCM, FRCPC, works in the Division of Rheumatology, in the Departments of Pediatrics and Medicine, The Hospital for Sick Children and University of Toronto, in Ontario, Canada.

References

1. Kile RL, Rusk HA. A case of cold urticaria with an unusual family history. JAMA. 1940;114(12):1067–1068.
2. Muckle TJ, Wells M. Urticaria, deafness and amyloidosis: A new heredo-familial syndrome. QJ Med. 1962 Apr;31:235–248.
3. Prieur AM, Griscelli C. Arthropathy with rash, chronic meningitis, eye lesions and mental retardation. J Pediatr. 1981 Jul;99(1):79–83.
4. Hoffman HM, Mueller JL, Brodie DH, et al. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet. 2001 Nov;29(3):301–305.
5. Hashkes PJ, Lovell DJ. Recognition of infantile-onset multisystem inflammatory disease as a unique entity. J Pediatr. 1997 Apr;130(4):513–515.
6. Feldmann J, Prieur AM, Quartier P, et al. Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am J Hum Genet. 2002 Jul;71(1):198–203.
7. Lainka E, Neudorf U, Lohse P, et al. Analysis of cryopyrin-associated periodic syndromes (CAPS) in German children: Epidemiological, clinical and genetic characteristics. Klin Padiatr. 2010 Nov;222(6):356–361.
8. Cuisset L, Jeru I, Dumont B, et al. Mutations in the autoinflammatory cryopyrin-associated periodic syndrome gene: Epidemiological study and lessons from eight years of genetic analysis in France. Ann Rheum Dis. 2011 Mar;70(3):495–499.
9. Aksentijevich I, D Putnam C, Remmers EF, et al. The clinical continuum of cryopyrinopathies: Novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum. 2007 Apr;56(4):1273–1285.
10. Krause K, Grattan CE, Bindslev-Jensen C, et al. How not to miss autoinflammatory diseases masquerading as urticaria. Allergy. 2012 Dec;67(12):1465–1474.
11. Kitley JL, Lachmann HJ, Pinto A, Ginsberg L. Neurologic manifestations of the cryopyrin-associated periodic syndrome. Neurology. 2010 Apr;74(16):1267–1270.
12. Toplak N, Frenkel J, Ozen S, et al. An international registry on autoinflammatory diseases: The Eurofever experience. Ann Rheum Dis. 2012 Jul;71(7):1177–1182.
13. Kuemmerle-Deschner JB, Dembi Samba S, Tyrrell PN, et al. Challenges in diagnosing Muckle-Wells syndrome: Identifying two distinct phenotypes. Arthritis Care Res (Hoboken). 2014 May;66(5):765–772.
14. Kuemmerle-Deschner JB, Koitschev A, Ummenhofer K, et al. Hearing loss in Muckle-Wells syndrome. Arthritis Rheum. 2013 Mar;65(3):824–831.
15. Kuemmerle-Deschner JB, Lohse P, Koetter I, et al. NLRP3 E311K mutation in a large family with Muckle-Wells syndrome—Description of a heterogeneous phenotype and response to treatment. Arthritis Res Ther. 2011;13(6):R196.
16. Tanaka N, Izawa K, Saito MK, et al. High incidence of NLRP3 somatic mosaicism in patients with chronic infantile neurologic, cutaneous, articular syndrome: Results of an International Multicenter Collaborative Study. Arthritis Rheum. 2011 Nov;63(11):3625–3632.
17. Nakagawa K, Gonzalez-Roca E, Souto A, et al. Somatic NLRP3 mosaicism in Muckle-Wells syndrome. A genetic mechanism shared by different phenotypes of cryopyrin-associated periodic syndromes. Ann Rheum Dis. 2013 Dec 10; [Epub ahead of print].
18. Mariathasan S, Weiss DS, Newton K, et al. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature. 2006 Mar 9;440(7081):228–232.
19. Lee GS, Subramanian N, Kim AI, et al. The calcium-sensing receptor regulates the NLRP3 inflammasome through Ca2+ and cAMP. Nature. 2012 Dec 6;492(7427):123–127.
20. Gattorno M, Tassi S, Carta S, et al. Pattern of interleukin-1beta secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations. Arthritis Rheum. 2007 Sep;56(9):3138–3148.
21. Lasigliè D, Traggiai E, Federici S, et al. Role of IL-1 beta in the development of human T(H)17 cells: Lesson from NLPR3 mutated patients. PLoS One. 2011;6(5):e20014.
22. Brydges SD, Broderick L, McGeough MD, et al. Divergence of IL-1, IL-18, and cell death in NLRP3 inflammasomopathies. J Clin Invest. 2013 Nov 1;123(11):4695–4705.
23. Wittkowski H, Kuemmerle-Deschner JB, Austermann J, et al. MRP8 and MRP14, phagocyte-specific danger signals, are sensitive biomarkers of disease activity in cryopyrin-associated periodic syndromes. Ann Rheum Dis. 2011 Dec;70(12):2075–2081.
24. Carta S, Tassi S, Delfino L, et al. Deficient production of IL-1 receptor antagonist and IL-6 coupled to oxidative stress in cryopyrin-associated periodic syndrome monocytes. Ann Rheum Dis. 2012 Sep;71(9):1577–1581.
25. Satoh T, Kambe N, Matsue H. NLRP3 activation induces ASC-dependent programmed necrotic cell death, which leads to neutrophilic inflammation. Cell Death Dis. 2013 May 23;4:e644.
26. Martinon F, Petrilli V, Mayor A, et al. Gout associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006 Mar 9;440(7081):237–241.
27. Dinarello CA. Blocking interleukin-1β in acute and chronic autoinflammatory diseases. J Intern Med. 2011 Jan;269(1):16–28.
28. Hoffman HM, Throne ML, Amar NJ, et al. Efficacy and safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated periodic syndromes. Arthritis Rheum. 2008 Aug;58(8):2443–2452.
29. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al, for the Canakinumab in CAPS Study Group. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med. 2009 Jun 4;360(23):2416–2425.
30. Goldbach-Mansky R, Dailey NJ, Canna SW, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1 beta inhibition. N Engl J Med. 2006 Aug 10;355(6):581–592.
31. Kuemmerle-Deschner JB, Hachulla E, Cartwright R, et al. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis. 2011 Dec;70(12):2095–2102.
32. Lachmann HJ, Lowe P, Felix SD, et al. In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J Exp Med. 2009 May 11;206(5):1029–1036.
33. Sibley CH, Plass N, Snow J, et al. Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: A cohort study to determine three- and five-year outcomes. Arthritis Rheum. 2012 Jul;64(7):2375–2386.
34. Almeida MQ, Tsang KM, Cheadle C, et al. Protein kinase A regulates caspase-1 via Ets-1 in bone stromal cell-derived lesions: A link between cyclic AMP and pro-inflammatory pathways in osteoblast progenitors. Hum Mol Genet. 2011 Jan 1;20(1):165–175.
35. Caorsi R, Lepore L, Zulian F, et al. The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age. Arthritis Res Ther. 2013 Feb 26;15(1):R33.
36. Galea J, Ogungbenro K, Hulme S, et al. Intravenous anakinra can achieve experimentally effective concentrations in the central nervous system within a therapeutic time window: Results of a dose-ranging study. J Cereb Blood Flow Metab. 2011 Feb;31(2):439–447.